337 related articles for article (PubMed ID: 34419523)
1. Infantile hemangioma. Part 2: Management.
Sebaratnam DF; Rodríguez Bandera AL; Wong LF; Wargon O
J Am Acad Dermatol; 2021 Dec; 85(6):1395-1404. PubMed ID: 34419523
[TBL] [Abstract][Full Text] [Related]
2. Beta blocker treatment for infantile hemangiomas.
Rouhana HF; Fruge JH; Massengale WT
Dermatol Online J; 2015 Jul; 21(7):. PubMed ID: 26436966
[TBL] [Abstract][Full Text] [Related]
3. Review of topical beta blockers as treatment for infantile hemangiomas.
Painter SL; Hildebrand GD
Surv Ophthalmol; 2016; 61(1):51-8. PubMed ID: 26408055
[TBL] [Abstract][Full Text] [Related]
4. Local administration of β-blockers for infantile hemangiomas: a systematic review and meta-analysis.
Ovadia SA; Landy DC; Cohen ER; Yang EY; Thaller SR
Ann Plast Surg; 2015 Feb; 74(2):256-62. PubMed ID: 25590249
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas.
Mashiah J; Kutz A; Rabia SH; Ilan EB; Goldberg I; Sprecher E; Harel A
Int J Dermatol; 2017 Feb; 56(2):148-153. PubMed ID: 28074521
[TBL] [Abstract][Full Text] [Related]
6. Outpatient use of oral propranolol and topical timolol for infantile hemangiomas: survey results and comparison with propranolol consensus statement guidelines.
Kumar MG; Coughlin C; Bayliss SJ
Pediatr Dermatol; 2015; 32(2):171-9. PubMed ID: 25556828
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage: A Randomized Clinical Trial.
Muñoz-Garza FZ; Ríos M; Roé-Crespo E; Bernabeu-Wittel J; Montserrat-García MT; Puig L; Gich I; Baselga E
JAMA Dermatol; 2021 May; 157(5):583-587. PubMed ID: 33825828
[TBL] [Abstract][Full Text] [Related]
8. Recurrence of infantile hemangioma after termination of propranolol treatment.
Chang L; Ma G; Jin Y; Ye X; Qiu Y; Chen H; Yu W; Yang X; Hu X; Lin X
Ann Plast Surg; 2014 Feb; 72(2):173-5. PubMed ID: 24406852
[TBL] [Abstract][Full Text] [Related]
9. Effect of topical propranolol gel on plasma renin, angiotensin II and vascular endothelial growth factor in superficial infantile hemangiomas.
Tang YJ; Zhang ZZ; Chen SQ; Chen SM; Li CJ; Chen JW; Yuan B; Xia Y; Wang L
J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):759-762. PubMed ID: 26489635
[TBL] [Abstract][Full Text] [Related]
10. β-blockers in the treatment of periocular infantile hemangioma.
Al-Haddad C; El Salloukh NA; El Moussawi Z
Curr Opin Ophthalmol; 2019 Sep; 30(5):319-325. PubMed ID: 31394556
[TBL] [Abstract][Full Text] [Related]
11. Topical Timolol Maleate 0.5% for Infantile Hemangioma: Its Effectiveness Compared to Ultrapotent Topical Corticosteroids - A Single-Center Experience of 278 Cases.
Danarti R; Ariwibowo L; Radiono S; Budiyanto A
Dermatology; 2016; 232(5):566-571. PubMed ID: 27592104
[TBL] [Abstract][Full Text] [Related]
12. Treatment of problematic infantile hemangiomas with propranolol: a series of 40 cases and review of the literature.
Oksiuta M; Matuszczak E; Dębek W; Dzienis-Koronkiewicz E; Hermanowicz A; Tylicka M
Postepy Hig Med Dosw (Online); 2014 Sep; 68():1138-44. PubMed ID: 25228522
[TBL] [Abstract][Full Text] [Related]
13. Is Routine Electrocardiography Necessary Before Initiation of Propranolol for Treatment of Infantile Hemangiomas?
Yarbrough KB; Tollefson MM; Krol AL; Leitenberger SL; Mann JA; MacArthur CJ
Pediatr Dermatol; 2016 Nov; 33(6):615-620. PubMed ID: 27599450
[TBL] [Abstract][Full Text] [Related]
14. [Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas].
Zheng JW; Wang XK; Jiang CH; Qin ZP; Fan XD; Yang YW; Huo R; Liu SH; Zhao JH; Wang XY; Zhou DK; Lei SR
Shanghai Kou Qiang Yi Xue; 2016 Dec; 25(6):744-747. PubMed ID: 28275803
[TBL] [Abstract][Full Text] [Related]
15. Multiple pulmonary infantile hemangiomas responsive to oral propranolol.
Galdeano F; Herón A; Moreno S; Aprea G; Meneses M; Torrelo A
Pediatr Dermatol; 2021 Jan; 38(1):226-228. PubMed ID: 33155718
[TBL] [Abstract][Full Text] [Related]
16. News on infantile haemangioma. Part 2: therapy and evaluation.
Saerens J; De Leye H; Janmohamed SR
Clin Exp Dermatol; 2021 Apr; 46(3):480-486. PubMed ID: 33539606
[TBL] [Abstract][Full Text] [Related]
17. Infantile hemangiomas, complications and treatments.
Cheng CE; Friedlander SF
Semin Cutan Med Surg; 2016 Sep; 35(3):108-16. PubMed ID: 27607318
[TBL] [Abstract][Full Text] [Related]
18. Infantile Hemangioma: A Current Review.
Pahl KS; McLean TW
J Pediatr Hematol Oncol; 2022 Mar; 44(2):31-39. PubMed ID: 34966091
[TBL] [Abstract][Full Text] [Related]
19. Clinical Features, Prognostic Factors, and Treatment Interventions for Ulceration in Patients With Infantile Hemangioma.
Fernández Faith E; Shah S; Witman PM; Harfmann K; Bradley F; Blei F; Pope E; Alsumait A; Gupta D; Covelli I; Streicher JL; Cotton C; Tollefson M; Nguyen H; Hunt R; Moore-Clingenpeel M; Frieden IJ
JAMA Dermatol; 2021 May; 157(5):566-572. PubMed ID: 33787840
[TBL] [Abstract][Full Text] [Related]
20. Residual Lesions After Pharmacological and Dye-Laser Treatment of Infantile Hemangiomas: Critical Review of 432 Cases.
Chelleri C; Monzani NA; Gelmetti C; Milani GP; Fossali EF; Galeone C; Cavalli R
Lasers Surg Med; 2020 Sep; 52(7):597-603. PubMed ID: 31828809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
